HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health And Wellness Executive Decisions: CHPA Counsel, CRN SVP, Gellar For Colgate

Executive Summary

CHPA appoints Anne Marie Murphy deputy general counsel; CRN promotes Andrew Wong to senior VP, scientific and regulatory affairs; and Sarah Michelle Gellar promotes the Colgate Optic White High Impact line.

You may also be interested in...



P&G Olay Play Could Shift Women's Products Advertising During Super Bowl

Olay skin care ad during Super Bowl with actress Sarah Michelle Geller could usher in era of for women’s products during the event. Marketing experts say as advertisers look to identify more with women’s issues and take on political or social bents, they should tie brands with messaging that is straightforward.

People In Brief: Pfizer, Valeant, Vitalah, Aker, Mulberry Love

Schulman out, Bourla in at Pfizer; Valeant appoints Kellen chairman; Vitalah VP leads Oxylent sales; Aker names Australia head; CRN builds regulatory team; more People In Brief.

Pipeline Watch: Four Approvals And 21 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel